Objective: After menopause, women experience changes in body composition, especially an increase in fat mass. In addition, advancing age, decreased physical activity, and increased inflammation may predispose them to develop type 2 diabetes. Isoflavones have been shown to improve metabolic parameters in postmenopausal women. However, the effect of isoflavones on adipokines/cytokines remains unclear. The purpose of this study was to evaluate the effect of high-dose isoflavones on inflammatory and metabolic markers in postmenopausal women.
M enopause is characterized by the cessation of menses because of loss of ovarian follicular activity. This typically occurs around the ages of 45 to 55 years and is characterized by hot flashes, decreased libido, and changes in body composition. 1, 2 These changes occur in the setting of decreasing estradiol, advancing age, and changes in lifestyle that include lack of exercise and decreased fitness. These factors influence lipid and carbohydrate metabolism and may contribute to insulin resistance and diabetes in these women.
Changes in glucose homeostasis may be influenced by adipokines such as adiponectin, leptin, and resistin. The influence of hormonal alterations during menopause on circulating levels of these adipokines remains unclear. 3, 4 Leptin and resistin are known to increase in correlation to body fat, which has been found to mediate insulin resistance. 5 Proinflammatory cytokines, such as tumor necrosis factor > (TNF->) and interleukin-6 (IL-6), are also produced by adipose tissue and are implicated in the pathogenesis of insulin resistance and diabetes. 6 Because inflammation increases with aging, these cytokines may also contribute to insulin resistance in postmenopausal women. 3 In an effort to alleviate the effects of menopause, hormone therapy with estrogen has been used for decades. However, recent studies have shown an increased risk of cardiovascular disease with estrogen replacement. 7, 8 Hence, a drive to find more natural sources of estrogen has been iniated. Phytoestrogens are plant compounds with estrogen-like biological activity. 9, 10 There are three main classes of phytoestrogens: isoflavones, lignans, and coumestans. 9 Main sources of isoflavones include soy beans, flaxseed, legumes, and others, with the major isoflavones being genistein, daidzein, and glycitein. Phytoestrogens exhibit both estrogenic and antiestrogenic actions in vitro and in vivo, binding to the estrogen receptor and initiating transcriptional activity. 11 Postmenopausal Japanese women have been reported to have a lower incidence of vasomotor symptoms, which is believed to be due partly to the high isoflavone content of their diet. 9 Epidemiological studies have shown that Japanese-American women in Seattle have a higher prevalence of type 2 diabetes and insulin resistance than do those living in Tokyo. 12, 13 It is therefore thought that isoflavones in amounts similar to that used in Asian diets may protect against these metabolic perturbations.
Inclusion of isoflavones in the diet of postmenopausal women with type 2 diabetes and metabolic syndrome has been shown to improve glycemic control, insulin resistance, and hemoglobin A 1c . 14, 15 However, the effect of isoflavones on metabolic and inflammatory markers such as fasting glucose, insulin resistance, ghrelin, adipokines, and cytokines in healthy postmenopausal women is unclear. This study was conducted to answer this question.
METHODS

Participants and study design
Participants were ambulatory, community-dwelling, English-speaking women who were postmenopausal (natural and surgical) and had a serum follicle-stimulating hormone (FSH) level of greater than 30 mIU/mL and were recruited from the community (Baltimore metropolitan area) by advertising in newspapers and through study flyers and referrals from community physicians. Women taking estrogen were asked to discontinue therapy at least three months before enrollment. Women already taking soy supplements (soy milk, black cohosh, etc) were asked to discontinue these products for the duration of the study. Those who refused were excluded. Other exclusions included allergy to soy protein, history of breast cancer or abnormal mammograms, current use of glucocorticoids, serum triglycerides greater than 500 mg/dL, diabetes, liver disease, untreated thyroid disease, neurological disease, and untreated psychiatric disorders. All participants provided informed consent, and the study was approved by the Johns Hopkins Institutional Review Board.
Randomization
Before recruitment, randomized numbers were generated by computer and assigned to soy protein versus placebo group. Both participants and study personnel were blinded to the group assignment. Nonstudy personnel dispensed the drug.
Intervention
The intervention was in the form of a soy powder (Revival Soy, Physicians Pharmaceuticals, Inc, Kernersville, NC) containing 20 g of soy protein consisting of 160 mg total isoflavones (96 mg aglycones). The powder could be mixed with milk and other beverages. Isoflavone concentrations were 64 mg genistein, 63 mg daidzein, and 34 mg glycitein. Placebo powder (Physicians Pharmaceuticals, Inc, Kernersville, NC) contained 20 g of whole milk protein and equivalent nutrients contained in the active product, excluding isoflavones. Active and placebo powders were available in vanilla and chocolate flavors (dispensed according to participant's taste preference) and looked and tasted similar. Women were asked to consume one packet daily. Supplements were dispensed at baseline and at the 6-week visit. Compliance was judged by counting the number of unused packets returned by women at weeks 6 and 12 of the study. This was then converted to percentage of prescribed packets that were ingested by the women. The women also reported days when packets were missed.
Laboratory methods
Blood samples were collected from women at baseline and at week 12 visits between 8 and 10 AM after an overnight fast. Once collected, samples were centrifuged to separate serum that was used for all hormone measurements. Serum was stored at j80-C until assayed. Every assay was performed in duplicate for all women simultaneously and with the same standard curve to minimize errors.
Glycemic parameters
Serum glucose concentrations were quantified using a Beckman Glucose Analyzer 2 (Beckman Instruments, Inc, Fullerton, CA). This analyzer uses an oxygen rate method with an oxygen electrode. A sample is injected into enzyme reagent solution containing dissolved oxygen, and electronic circuitry is used to measure the rate of oxygen consumption from the sample, which is directly proportional to the glucose concentration. Precision for these glucose values had an SD of less than 2.5 mg/dL. Insulin concentrations were determined using a solid phase twosite enzyme immunoassay (Alpco Diagnostics, Salem, NH) with intra-assay and interassay variation between 2.6% and 3.4%. Insulin resistance was assessed by using the homeostasis model assessment (HOMA IR ) method [HOMA IR = (glucose [mmol] Â insulin [KIU/mL]) /22]. 16 FIG. 1. Comparison of change in plasma glucose, insulin, adipokines, and homeostasis model assessment IR measured between the placebo and soy arms at 12 weeks using unpaired t tests.
Adipokines/cytokines
Serum leptin and resistin were measured using enzymelinked immunosorbent assays. Resistin (Alpco Diagnostics, Salem, NH) had intra-assay variations between 2.8% and 3.4% and interassay variation between 5.1% and 6.9%. The human leptin kit uses a direct sandwich-based method (Linco Research, St Charles, MO). The coefficients of intra-assay and interassay variation were between 2.6% and 6.2%. Total ghrelin concentrations were calculated using a competitive radioimmunoassay (Phoenix Pharmaceuticals, Inc, Burlingame, CA). The intra-assay and interassay variations were between 6.7% and 15.3%. Adiponectin measurements also used radioimmunoassay (Linco Research) with intra-assay and interassay variations between 1.78% and 9.24%. The quantitative sandwich enzyme immunoassay technique (R&D Systems, Minneapolis, MN) was used for both IL-6 and TNF->. The intra-assay and interassay precision for IL-6 was between 6.5% and 9.6%, with a range of 0.428 to 8.87 pg/ mL. The detection range of TNF-> was 0.585 to 2.139 pg/ mL with an intra-assay and interassay variation between 3.1% and 10.6%. All interassay coefficients of variation were based on duplicate samples on more than one plate, using one standard curve.
Statistical analysis
Before testing the hypotheses and modeling, normality of the continuous variables was inspected by plotting histograms and via the Shapiro-Wilks test, the need for nonparametric analysis was determined. Comparisons of the changes in hormone measurements within treatment groups were measured using unpaired t tests. For comparison between treatment groups, analysis was done for categorical demographic variables in Table 1 using W 2 tests. Comparisons between treatment groups of the changes in hormone measurements within groups shown in Figs. 1 and 2 were done using unpaired t tests. The level of statistical significance was set at P G 0.05.
RESULTS
Demographics
Ninety-three consecutive postmenopausal women were initially randomized. Two were excluded because of noncompliance, whereas seven withdrew because of adverse effects.
Hence, 84 women completed the original study evaluating quality of life and vasomotor symptoms. 17 Of these 84 women, 75 had serum samples of sufficient quantity for analysis of adipokines/cytokines and metabolic parameters (32 active, 43 placebo). Most women were white (86%). The mean age was 56 years for the placebo group and 57 years for the active group. The average time since menopause was 9 years, with two thirds of the participants experiencing natural menopause. No major differences were present at baseline between the two groups ( Table 1) .
Hormones and adipokines/cytokines
At baseline, the placebo group had significantly higher levels of TNF-> (P G 0.0001); otherwise, there was no difference in any other parameter. After 12 weeks of treatment, there were significant positive changes in TNF-> levels within the placebo group (P G 0.0001) and adiponectin levels within the isoflavones group (P = 0.03). Comparison of pre-post change between the groups showed a small but significant increase (P = 0.03) in serum adiponectin levels in the isoflavone group compared with the placebo group (Fig. 1) . No significant changes were seen in any other parameters between the two groups ( Figs. 1 and 2) .
DISCUSSION
Changes in glucose metabolism are seen in women after menopause that occurs in the setting of declining estrogen levels, advancing age, and alterations in fat distribution. 18 Several investigations have confirmed that insulin resistance is significantly higher in postmenopausal women compared with their premenopausal counterparts. 3 These factors may predispose these women to develop cardiovascular disease and type 2 diabetes. 19 Hormone therapy with estrogen has been shown to improve glucose homeostasis in some studies. 20, 21 However, unfortunately, hormone therapy has been associated with increased cardiovascular risk. 7, 8 In contrast, phytoestrogens have been associated with decreased cardiovascular risk. 22 Indeed, studies have shown improvement in inflammatory cytokines with isoflavone treatment 23 ; however, these findings have not been universal. 24 Our randomized, double-blind, placebo-controlled trial showed no significant benefits in any of the glycemic parameters after 3 months of high dose (160 mg) isoflavones despite a FIG. 2. Comparison of change in plasma cytokines measured between the placebo and soy arms at 12 weeks using unpaired t tests. IL-6, interlenkin-6; TNF->, tumor necrosis factor->. significant increase in serum adiponectin levels in the soy group.
Soy is a staple of diet in Asian countries, with consumption reaching as much as 50 to 100 mg daily. 25 In contrast, the estimated intake of isoflavones by American women is less than 1 mg/d. 26 Epidemiological data show that Japanese-Americans living in Seattle have a four times higher prevalence of type 2 diabetes than do those living in Tokyo. 12, 13 This suggests a beneficial role of soy on metabolic parameters. Indeed, studies assessing the effects of phytoestrogens in postmenopausal women with metabolic syndrome and type 2 diabetes have shown beneficial effects on glucose homeostasis. 14, 15 Jayagopal et al 15 have shown that 132 mg of isoflavones improves insulin resistance and hemoglobin A 1c in postmenopausal women with type 2 diabetes. The mechanisms behind the antidiabetic effects of isoflavones include inhibition of intestinal brush border uptake of glucose and tyrosine kinase inhibitory properties. 27 The hope has been that isoflavones will be a successful alternative for estrogen therapy, not only in terms of menopausal symptoms but also in other health benefits such as altered glucose metabolism and insulin resistance encountered with menopause. Unfortunately, the studies of isoflavones have shown inconsistent results on metabolic parameters in postmenopausal women. Nikander et al 28 used 114 mg of soy for 3 months in 56 women with breast cancer and found no beneficial effect on insulin sensitivity. Although we used a higher dose of isoflavones (160 mg) in healthy women, our results were similar to those of their study. One explanation of this lack of benefit could be the fact that these women were relatively healthy and close to ideal body weight. Hence, there may have been little room for improvement in their metabolic parameters despite a significant increase in serum adiponectin in the soy group.
Because there is an increase in fat mass with menopause, adipokines have been implicated in the pathogenesis of insulin resistance. 29 Increased serum resistin levels have been associated with glucose intolerance, whereas increased adiponectin levels, as occur with thiazolidinedione therapy, are associated with improved insulin sensitivity. 29 Our study showed that serum adiponectin levels increased in women taking high-dose isoflavones compared with placebo. Generally speaking, serum adiponectin levels are decreased in obesity and type 2 diabetes, and this is considered to be of etiological importance in causing insulin resistance. 4, 5 Therefore, any measure that increases adiponectin levels would be predicted to improve insulin resistance. However, because our participants had normal insulin sensitivity to start with (based on fasting insulin/glucose levels), we could not demonstrate any effect on metabolic parameters by increased adiponectin levels. However, in obese women or those with impaired glucose tolerance or diabetes, one may have seen the beneficial effect of rise in adiponectin levels on metabolic parameters.
The metabolic effects of ghrelin include increased appetite, glucose oxidation, and lipogenesis. 5 Contrary to our results, some studies have demonstrated decreased levels of ghrelin after as little as 8 weeks of low-dose isoflavones. 28 Further inconsistencies exist on the effects of phytoestrogens on inflammatory cytokines. Both TNF-> and IL-6 are known to cause insulin resistance. The former causes it directly by down-regulating insulin receptor substrate 1 (IRS-1), inducing serine phosphorylation of IRS-1, and decreasing glucose transporting protein-1. 29 On the other hand, IL-6 causes it by decreasing the activation of IRS-1. 29 Studies have suggested a decrease in the circulating levels of TNF-> after treatment with low-dose isoflavones in 12 postmenopausal women. 23 Although our study had a much higher sample size, we did not observe any decrease in these cytokines in the soy group compared with the placebo group. We believe that the anti-inflammatory role of soy should be further explored in large prospective trials in obese or insulin-resistant women.
Our study has a few limitations. First, we did not measure serum or urine levels of isoflavones; hence, it is uncertain how much of the soy protein was actually absorbed. The method of counting sachets, however, has been the most common method in many studies, and the compliance rate in our study was very high. Second, we did not measure body composition. Lastly, serum levels of adipokines and cytokines do not necessarily reflect tissue concentrations. Hence, any influence of isoflavones on tissue levels of these markers cannot be ruled out. Our study also has a few strengths. It has a reasonably large sample size compared with previous studies and the breadth of adipokines/cytokines measured affords some confidence to the results obtained.
CONCLUSIONS
In conclusion, supplementation with isoflavones at a concentration consumed by the Asian population did not infer any benefits on markers of glucose homeostasis (despite an increase in serum adiponectin levels). However, the role of soy in obese and diabetic postmenopausal women needs further exploration.
